100 related articles for article (PubMed ID: 1689986)
1. [Antitumor drugs and potentiators aiming circumvention of drug resistance].
Suzuki H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):335-41. PubMed ID: 1689986
[TBL] [Abstract][Full Text] [Related]
2. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
3. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells.
Michelutti A; Michieli M; Damiani D; Melli C; Ermacora A; Grimaz S; Candoni A; Russo D; Fanin R; Baccarani M
Haematologica; 1997; 82(2):143-7. PubMed ID: 9175315
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic and cytotoxic response of Ehrlich ascites tumor cells in vivo on chronic treatment with cytarabine, bleomycin, and peplomycin.
Stoehr M; Friedel G; Engel P; Goerttler K; Futterman G
Arzneimittelforschung; 1984; 34(4):451-4. PubMed ID: 6204650
[TBL] [Abstract][Full Text] [Related]
5. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
12. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
14. [Combined effect of bleomycin and SDB-ethylenediamine, a synthetic isoprenoid, on oral squamous carcinoma cell lines and transplantable nude mouse tumors].
Takahashi Y; Urade M; Kishimoto H; Arimoto T; Yanagisawa T; Yoshioka W
Gan To Kagaku Ryoho; 1995 Jun; 22(7):883-7. PubMed ID: 7540824
[TBL] [Abstract][Full Text] [Related]
15. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
16. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
20. The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells.
Tarasiuk J; Majewska E; Seksek O; Rogacka D; Antonini I; Garnier-Suillerot A; Borowski E
Biochem Pharmacol; 2004 Nov; 68(9):1815-23. PubMed ID: 15450947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]